Drug Profile

Belzupacap sarotalocan - Aura Biosciences/National Cancer Institute

Alternative Names: AU 011; Bel-sar; Belzupacap serotalocan; Light-activated AU-011

Latest Information Update: 30 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aura Biosciences; National Cancer Institute (USA)
Developer Aura Biosciences
Class Antineoplastics; Drug conjugates; Immunotherapies; Phthalocyanines; Viral proteins
Mechanism of Action Cell death stimulants; Photosensitisers; Reactive oxygen species stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Uveal melanoma
New Molecular Entity Yes

Highest Development Phases

Phase III Uveal melanoma
Phase I/II Bladder cancer
Preclinical Solid tumours

Most Recent Events

15 May 2025 Aura Biosciences files for patent protection with US PTO for Belzupacap sarotalocan in USA
15 May 2025 Phase-I/II clinical trials in Bladder cancer (Intratumoural)
24 Mar 2025 Aura Biosciences initiates a phase II trial in Uveal melanoma in USA (Intraocular) (NCT06643884)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com